RA
VOR icon

Rosalind Advisors’s Vor Biopharma VOR Stock Holding History

Rosalind Advisors’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Sell
648,600
-51,400
-7% -$778K 4.44% 9
2026
Q1 		$12.5M Buy
+700,000
New +$9.87M 5.02% 8
2024
Q4 		– Sell
-3,834
Closed -$53.7K – 50
2024
Q3 		$53.7K Buy
+3,834
New +$69.9K 0.03% 33

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Rosalind Advisors's VOR Position: Q2 2026 in Review

Rosalind Advisors reduced its Vor Biopharma (VOR) stake by 7.3% in Q2 2026, selling an estimated $778K and leaving 648,600 shares worth $11.9M. The position accounts for 4.44% of the portfolio, ranked #9.

Rosalind Advisors first reported a position in VOR in Q3 2024 and has held it in 3 quarters since. The position peaked at $12.5M in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Rosalind Advisors held 648,600 shares of Vor Biopharma worth $11.9M as of Q2 2026.
  • Rosalind Advisors sold 51,400 Vor Biopharma shares in Q2 2026, an estimated $778K.
  • Vor Biopharma made up 4.44% of Rosalind Advisors's portfolio in Q2 2026, its #9 holding.
  • Rosalind Advisors first reported a position in Vor Biopharma in Q3 2024 and has held it in 3 quarters since.
  • Rosalind Advisors's Vor Biopharma position peaked at $12.5M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.